Tauns Laboratories Profit Halves on Lower Sales but Keeps Full-Year Outlook and Dividend Plan

Tauns Laboratories, Inc. ( (JP:197A) ) just unveiled an announcement.

Tauns Laboratories reported a sharp year-on-year decline for the six months ended December 31, 2025, with net sales down 30.9% to ¥8.28 billion and net income dropping 56.0% to ¥2.06 billion, compressing margins and halving basic earnings per share. Despite the weaker interim results and a lower equity-to-asset ratio, the company raised its interim dividend to ¥14 per share and kept its full-year dividend forecast at ¥28, while projecting modest full-year sales growth of 11.5% and a 36.4% rise in full-year net income, signaling management’s confidence in earnings recovery and continued shareholder returns.

The balance sheet expanded with total assets rising to ¥44.20 billion, though net assets were largely flat and leverage increased compared with the previous fiscal year-end. The company left its full-year operating and ordinary income forecasts almost unchanged year on year, suggesting anticipated stability in core profitability even as it navigates a cooling revenue environment and potential market or pricing normalization after prior strong periods.

The most recent analyst rating on (JP:197A) stock is a Hold with a Yen613.00 price target. To see the full list of analyst forecasts on Tauns Laboratories, Inc. stock, see the JP:197A Stock Forecast page.

More about Tauns Laboratories, Inc.

Tauns Laboratories, Inc. is a Japan-based company listed on the Tokyo Stock Exchange that operates in the medical and diagnostics sector. It focuses on manufacturing and selling clinical testing-related products, with its financial reporting and dividend policies geared toward shareholders in the Japanese capital market.

Average Trading Volume: 528,877

Technical Sentiment Signal: Strong Buy

Current Market Cap: Yen59.59B

For a thorough assessment of 197A stock, go to TipRanks’ Stock Analysis page.